创新药周报20250713： 证券研究报告 证券分析师刘浩 执业编号：S0360520120002 邮箱：liuhao@hcyjs.com 联系人段江瑶 邮箱：duanjiangyao@hcyjs.com @2021 华创版权所有 第一部分 本周创新药重点关注 国内创新药回顾 02 全球首个口服HAE急性发作按需治疗药物获批上市 本报告由华创证券有限责任公司编制 卖的出价或询价。本报告所载信息均为个人观点，并不构成对所涉及证券的个人投资建议。 请仔细阅读PPT后部分的分析师声明及免责声明。 2025-07-13 全球新药速递 03 01 遗传性血管性水肿（HAE） 证券研究报告 致。 ┃ HAE诊断流程 ┃ HAE分型及特征 | HAE 分型 | 发病机制 | C1-INH 浓度 | CI-INH 功能 | | --- | --- | --- | --- | | HAE-C1-INH 1 型 | C1-INH 基因突变 | 降低 | 降低 | | HAE-C1-INH2 型 | C1-INH 基因突变 | 正常或增高 | 障低 | | HAE-nC1-INH | FXII、 ANGPTI、PLG 基因突变 | ...

部分 第 01 行情回顾 02 板块观点和投资组合 03 行业和个股事件 本周行情回顾 =半创研究 本周中信一级行业指数涨跌幅 本周涨幅排名前/后十名的股票 ST未名 -18.51 前沿生物-U 41.43% 7% -13.36% 神州细胞 美迪西 38.92% 6% 舒泰伸 联环药业 38.58% -11.61% 5%6 一品红 康辰药业 27.28% 4%6 海辰药业 启迪药业 26.89% 3% 华海药业 2% 华纳药厂 24.44% 1% 美诺华 浩欧博 22.72% os 永安药业 塞力医疗 22.06% 新闻 48 14 18 1987 1989 荣昌生物 福瑞股份 20.83% 8.84% 创新医疗 20.76% 广生堂 -8.66% 30% -10% -596 -15% 10% 证监会审核华创证券投资咨询业务资格批文号:证监许可(2009) 1210 号 第二部分 01 行情回顾 板块观点和投资组合 02 03 行业和个股事件 整体观点和投资主线 =半创研究 · 整体观点：当前医药板块的估值处于低位，公募基金（剔除医药基金）对医药板块的配置处于低位，考虑到美债利率等宏观环境 因素的积极恢复、大 ...

泽璟制药公告，公司在研产品注射用ZG006被国家药品监督管理局药品审评中心纳入突破性治疗品种公 示名单，适应症为ZG006单药治疗既往经含铂化疗及至少1种其它系统治疗后(三线及以上)复发或进展的 晚期小细胞肺癌患者。公示期为2025年7月9日至2025年7月16日。ZG006是一种针对两个不同DLL3表位 及CD3的三特异性T细胞衔接器，具有成为同类最佳分子的潜力。 ...

Core Viewpoint - The 2025 Lujiazui Forum will be held in Shanghai, coinciding with positive signals from multiple Sci-Tech Innovation Board companies, showcasing steady performance growth, breakthroughs in core technologies, and frequent buybacks to boost market confidence [1] Group 1: Business Performance Highlights - The integrated circuit industry is thriving, with companies reporting strong performance due to the recovery of the terminal consumer market. For instance, Beijing Jingyi Automation Equipment Technology Co., Ltd. expects revenue between 690 million to 720 million yuan for the first half of 2025, a year-on-year increase of 36.54% to 42.48% [2] - Ningbo YSIC Electronics Co., Ltd. anticipates a revenue growth of 16.60% to 28.88% for the first half of 2025, driven by improved delivery capabilities and rising utilization rates in advanced packaging product lines [2] - Xiamen Xatu New Energy Materials Co., Ltd. reported a sales volume of approximately 47,600 tons for new energy materials in the first five months, a year-on-year increase of about 20.95%. The demand for lithium cobalt oxide also surged, with sales reaching approximately 22,300 tons, up about 53% [3] - Hefei Chip Microelectronics Equipment Co., Ltd. signed seven equipment purchase contracts totaling 146 million yuan, demonstrating strong product competitiveness [3] Group 2: R&D Achievements - The Sci-Tech Innovation Board has effectively implemented reforms to support technological innovation and new productive forces, resulting in over 120,000 invention patents accumulated by the end of 2024, with more than 20,000 new patents in 2024 alone [4] - 109 companies have been recognized as "single champion" enterprises in manufacturing, reflecting the highest development levels in specific sectors [4] - Several biopharmaceutical companies have announced significant R&D progress, including Suzhou Zejing Biopharmaceutical Co., Ltd., which received approval for clinical trials of its drugs for advanced small cell lung cancer [5] Group 3: Buyback and Stake Increase Actions - Sci-Tech Innovation Board companies are actively implementing buyback and dividend strategies to enhance shareholder value and stabilize market expectations. On June 17, eight companies announced buyback plans with a total upper limit of 762 million yuan [6] - Approximately 60% of Sci-Tech Innovation Board companies have conducted share buybacks since listing, totaling over 40 billion yuan. In 2024, more than 440 companies proposed buyback and stake increase plans, with a total upper limit exceeding 37 billion yuan [6] - Notable buyback actions include Hefei Jinghe Integrated Circuit Co., Ltd., which has repurchased shares totaling 890 million yuan, and several companies have announced plans to cancel repurchased shares to enhance shareholder returns [6][7]